# Metabolomics and Genetic Diagnosing Pancreatic Neuroendocrine Tumors in MEN1 Patients

> **NCT03048266** · — · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 629 (estimated)

## Conditions studied

- Multiple Endocrine Neoplasia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03048266
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2015-11-05
- **Primary completion:** 2025-11-01
- **Final completion:** 2026-11-01
- **Target enrollment:** 629 (ESTIMATED)
- **Last updated:** 2019-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03048266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03048266, "Metabolomics and Genetic Diagnosing Pancreatic Neuroendocrine Tumors in MEN1 Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03048266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*